Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022

Vaccine Market by Technology (Live, Conjugate, Toxoid, Recombinant), Disease (Influenza, DTaP, HPV, Hepatitis, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, Rabies), Route (IM, SC, ID, Oral), End User (Pediatric, Adult) & Type - Forecast to 2022

“Global vaccines market projected to grow at a CAGR of 7.5%”
The vaccines market is expected to reach USD 49.27 billion by 2022 from USD 34.30 billion in 2017, at a CAGR of 7.5%. Rising prevalence of diseases, increasing government and nongovernment funding for vaccine development, and increasing investments by companies are driving the growth of the vaccines market. On the other hand, market growth may be hindered due to the high cost of vaccine development and product recalls.

“Conjugate vaccines are expected to dominate the market during the forecast period.”
By technology, the vaccines market is segmented into conjugate vaccines, inactivated and subunit vaccines, live attenuated vaccines, recombinant vaccines, and toxoid vaccines. The conjugate segment is expected to hold the largest share of the market in 2017 and is also projected to register the highest CAGR during the forecast period. Rising prevalence of diseases and increasing government investments are the key factors driving the growth of this segment.

“Monovalent vaccines segment expected to hold the largest share of the market in 2017.”
Based on type, the vaccines market is segmented into monovalent vaccines and multivalent vaccines. The monovalent segment is expected to dominate this market with the largest share due to increasing investments by companies to develop new vaccines.

“Pneumococcal disease segment is expected to witness high growth during the forecast period”
Based on the disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, dengue, and other disease indications. The pneumococcal segment is expected to account for the largest share and is projected to register the highest rate during the forecast period. The growth in this segment can primarily be attributed to increasing government investments in pneumococcal vaccination programs and high incidence of pneumococcal disease.

“Asia to witness high growth during the forecast period”
In 2017, North America is expected to account for the largest share of the market followed by Europe. However, Asia is expected to register the highest CAGR during the forecast period. The high growth in this segment is attributed to the increasing investments by companies in India and China, rising disposable income, growing number of awareness programs and symposia, and growing venture capital investments.

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 – 36%; Tier 2 - 41%; Tier 3 - 23%.
• By Designation (Supply Side): C-level - 25%; D-level - 29%; Others - 46%.
• By Designation (Demand Side): General Physicians - 38%; Purchase Managers - 29%; Medical Researchers - 33%.
• By Region: North America - 40%; Europe - 20%; Asia - 33%; RoW - 7%.

List of companies profiled in the report
• GlaxoSmithKline plc
• Pfizer, Inc.
• Merck & Co., Inc.
• Sanofi Pasteur SA
• CSL Limited
• Emergent BioSolutions, Inc.
• Johnson & Johnson
• MedImmune, LLC
• Astellas Pharma Inc.
• Serum Institute of India
• Bavarian Nordic
• Mitsubishi Tanabe Pharma Corporation
• Daiichi Sankyo Company, Limited
• Protein Science Corporation
• Panacea Biotec

Research Coverage:
The report provides an overview of the vaccines market. It aims at estimating the market size and future growth potential of this market across different segments such as technology, type, disease indication, route of administration, end user, and region. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help the market leaders/new entrants in this market by providing them with the closest approximations of revenues for the overall vaccines market and its subsegments. This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies make suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.


  • INTRODUCTION
    • OBJECTIVES OF THE STUDY
    • MARKET DEFINITION
    • MARKET SCOPE
      • MARKET COVERED
      • YEARS CONSIDERED FOR THE STUDY
    • CURRENCY
    • LIMITATION
    • MARKET STAKEHOLDERS
  • RESEARCH METHODOLOGY
    • SECONDARY DATA
    • PRIMARY DATA
    • KEY INDUSTRY INSIGHTS
    • MARKET SIZE ESTIMATION
    • MARKET BREAKDOWN AND DATA TRIANGULATION
    • MARKET SHARE ESTIMATION
    • ASSUMPTIONS FOR THE STUDY
  • EXECUTIVE SUMMARY
  • PREMIUM INSIGHTS
    • OVERVIEW OF THE VACCINES MARKET
    • VACCINES MARKET, BY TYPE, 2017-2022
    • VACCINES MARKET, BY END USER, 2017 VS. 2022 (USD BILLION)
    • GEOGRAPHIC ANALYSIS: VACCINES MARKET, BY TECHNOLOGY
    • VACCINES MARKET, BY ROUTE OF ADMINISTRATION,
    • GEOGRAPHICAL SNAPSHOT OF THE VACCINES MARKET
  • MARKET OVERVIEW
    • INTRODUCTION
    • MARKET DYNAMICS
      • DRIVERS
        • Table INCIDENCE OF DISEASES, 2015
        • Table NIH FUNDING FOR VACCINE RESEARCH, 2012-2017 (USD MILLION)
      • RESTRAINTS
      • OPPORTUNITIES
      • CHALLENGES
        • Table IMMUNIZATION COVERAGE, BY DISEASE, 2014 VS 2015
      • BURNING ISSUES
  • INDUSTRY INSIGHTS
    • INVESTMENT ANALYSIS
    • REGULATORY LANDSCAPE
      • NORTH AMERICA
      • EUROPE
        • Table REGULATORY AUTHORITIES IN EUROPE
      • ASIA
        • Table REGULATORY AUTHORITIES IN ASIA
      • ROW
    • KEY PIPELINE PRODUCTS
      • Table KEY PIPELINE VACCINES
    • NEW VACCINE OPPORTUNITIES
      • HIV
        • Table ESTIMATED INVESTMENT IN HIV VACCINES, BY INVESTOR (2015-2016)
      • MALARIA
      • ZIKA
      • EBOLA
        • Table EBOLA PROJECTS FUNDED BY EUROPEAN COMMISSION (2014-2020)
  • VACCINES MARKET, BY TECHNOLOGY
    • INTRODUCTION
      • Table VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
    • CONJUGATE VACCINES
      • Table COST OF MENINGOCOCCAL CONJUGATE VACCINES
      • Table CONJUGATE VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
    • INACTIVATED AND SUBUNIT VACCINES
      • Table EXAMPLES OF INACTIVATED AND SUBUNIT VACCINES
      • Table INACTIVATED AND SUBUNIT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
    • LIVE ATTENUATED VACCINES
      • Table LIVE ATTENUATED VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
    • RECOMBINANT VACCINES
      • Table EXAMPLES OF RECOMBINANT VACCINES
      • Table RECOMBINANT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
    • TOXOID VACCINES
      • Table TOXOID VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • ACCINES MARKET, BY TYPE
    • INTRODUCTION
      • Table VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION)
    • MONOVALENT VACCINES
      • Table MONOVALENT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
    • MULTIVALENT VACCINES
      • Table EXAMPLES OF NOTABLE MULTIVALENT VACCINES AVAILABLE IN THE MARKET
      • Table MULTIVALENT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
  • VACCINES MARKET, BY DISEASE INDICATION
    • INTRODUCTION
      • Table VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION)
    • PNEUMOCOCCAL DISEASE
      • Table LIST OF COMMERCIALLY AVAILABLE PNEUMOCOCCAL VACCINES IN THE MARKET
      • Table VACCINES MARKET FOR PNEUMOCOCCAL DISEASE, BY REGION, 2015-2022 (USD MILLION)
    • DTP
      • Table LIST OF COMMERCIALLY AVAILABLE DTP VACCINES IN THE MARKET
      • Table VACCINES MARKET FOR DTP, BY REGION, 2015-2022 (USD MILLION)
    • INFLUENZA
      • Table LIST OF COMMERCIALLY AVAILABLE INFLUENZA VACCINES IN THE MARKET
      • Table VACCINES MARKET FOR INFLUENZA, BY REGION, 2015-2022 (USD MILLION)
    • HUMAN PAPILLOMA VIRUS
      • Table LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET
      • Table VACCINES MARKET FOR HPV, BY REGION, 2015-2022 (USD MILLION)
    • MENINGOCOCCAL DISEASE
      • Table LIST OF COMMERCIALLY AVAILABLE HPV VACCINES IN THE MARKET
      • Table VACCINES MARKET FOR MENINGOCOCCAL DISEASE, BY REGION, 2015-2022 (USD MILLION)
    • POLIO
      • Table LIST OF COMMERCIALLY AVAILABLE POLIO VACCINES IN THE MARKET
      • Table VACCINES MARKET FOR POLIO, BY REGION, 2015-2022 (USD MILLION)
    • ROTAVIRUS
      • Table LIST OF COMMERCIALLY AVAILABLE ROTAVIRUS VACCINES IN THE MARKET
      • Table VACCINES MARKET FOR ROTAVIRUS, BY REGION, 2015-2022 (USD MILLION)
    • HEPATITIS
      • Table LIST OF COMMERCIALLY AVAILABLE HEPATITIS VACCINES IN THE MARKET
      • Table VACCINES MARKET FOR HEPATITIS, BY REGION, 2015-2022 (USD MILLION)
    • MMR
      • Table LIST OF COMMERCIALLY AVAILABLE MMR VACCINES IN THE MARKET
      • Table VACCINES MARKET FOR MMR, BY REGION, 2015-2022 (USD MILLION)
    • VARICELLA
      • Table LIST OF COMMERCIALLY AVAILABLE VARICELLA VACCINES IN THE MARKET
      • Table VACCINES MARKET FOR VARICELLA, BY REGION, 2015-2022 (USD MILLION)
    • DENGUE
    • OTHER DISEASE INDICATIONS
      • Table LIST OF COMMERCIALLY AVAILABLE VACCINES FOR OTHER DISEASE INDICATIONS IN THE MARKET
      • Table VACCINES MARKET FOR OTHER DISEASE INDICATIONS, BY REGION, 2015-2022 (USD MILLION)
  • VACCINES MARKET, BY ROUTE OF ADMINISTRATION
    • INTRODUCTION
      • Table VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
    • INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION
      • Table VACCINES MARKET FOR INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION, BY REGION, 2015-2022 (USD MILLION)
    • ORAL ADMINISTRATION
      • Table VACCINES MARKET FOR ORAL ADMINISTRATION, BY REGION, 2015-2022 (USD MILLION)
    • OTHER ROUTES OF ADMINISTRATION
      • Table VACCINES MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2015-2022 (USD MILLION)
  • VACCINES MARKET, BY END USER
    • INTRODUCTION
      • Table VACCINES MARKET SIZE, BY END USER, 2015-2022 (USD MILLION)
    • PEDIATRICS
      • Table PEDIATRIC VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: PEDIATRIC VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
    • ADULTS
      • Table ADULT VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: ADULT VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
  • VACCINES MARKET, BY REGION
    • INTRODUCTION
      • Table VACCINES MARKET, BY REGION, 2015-2022 (USD MILLION)
    • NORTH AMERICA
      • Table NORTH AMERICA: VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
      • Table NORTH AMERICA: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION)
      • U.S.
        • Table U.S.: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
        • Table U.S.: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION)
      • CANADA
        • Table CANADA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
        • Table CANADA: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION)
    • EUROPE
      • Table EUROPE: VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
      • Table EUROPE: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
      • Table EUROPE: VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION)
      • Table EUROPE: VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION)
      • Table EUROPE: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
      • Table EUROPE: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION)
      • GERMANY
        • Table GERMANY: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
      • U.K.
        • Table U.K.: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
      • FRANCE
        • Table FRANCE: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
      • ITALY
        • Table ITALY: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
      • SPAIN
        • Table SPAIN: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
      • REST OF EUROPE (ROE)
        • Table ROE: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
    • ASIA
      • Table ASIA: HEALTH EXPENDITURE PER CAPITA, BY COUNTRY, 2000 & 2014 (USD)
      • Table ASIA: VACCINES MARKET, BY COUNTRY, 2015-2022 (USD MILLION)
      • Table ASIA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
      • Table ASIA: VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION)
      • Table ASIA: VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION)
      • Table ASIA: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
      • Table ASIA: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION)
      • JAPAN
        • Table JAPAN: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
      • CHINA
        • Table CHINA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
      • INDIA
        • Table INDIA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
      • REST OF ASIA (ROA)
        • Table ROA: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
    • REST OF THE WORLD (ROW)
      • Table ROW: VACCINES MARKET, BY TECHNOLOGY, 2015-2022 (USD MILLION)
      • Table ROW: VACCINES MARKET, BY TYPE, 2015-2022 (USD MILLION)
      • Table ROW: VACCINES MARKET, BY DISEASE INDICATION, 2015-2022 (USD MILLION)
      • Table ROW: VACCINES MARKET, BY ROUTE OF ADMINISTRATION, 2015-2022 (USD MILLION)
      • Table ROW: VACCINES MARKET, BY END USER, 2015-2022 (USD MILLION)
  • COMPETITIVE LANDSCAPE
    • INTRODUCTION
    • MARKET SHARE ANALYSIS
    • COMPETITIVE LEADERSHIP MAPPING
      • VISIONARY LEADERS
      • INNOVATORS
      • DYNAMIC DIFFERENTIATORS
      • EMERGING COMPANIES
    • STRENGTH OF PRODUCT PORTFOLIO (FOR 25 PLAYERS)
    • BUSINESS STRATEGY EXCELLENCE (FOR 25 PLAYERS)
  • COMPANY PROFILES
    • PFIZER, INC.
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • GLAXOSMITHKLINE PLC.
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • MERCK & CO., INC.
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • SANOFI PASTEUR SA
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • CSL LIMITED
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • EMERGENT BIOSOLUTIONS, INC.
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • JOHNSON & JOHNSON
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • MEDIMMUNE, LLC (A SUBSIDIARY OF ASTRAZENECA)
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • ASTELLAS PHARMA, INC.
      • OVERVIEW
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • SERUM INSTITUTE OF INDIA
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • BAVARIAN NORDIC
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • MITSUBISHI TANABE PHARMA CORPORATION
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • DAIICHI SANKYO COMPANY, LIMITED
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • PROTEIN SCIENCES CORPORATION
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
    • PANACEA BIOTEC
      • OVERVIEW
      • PRODUCTS OFFERED
      • STRENGTH OF PRODUCT PORTFOLIO
      • BUSINESS STRATEGY EXCELLENCE
      • RECENT DEVELOPMENTS (2014-2017)
  • APPENDIX
    • INSIGHTS OF INDUSTRY EXPERTS
    • DISCUSSION GUIDE
    • KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
    • INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
    • AVAILABLE CUSTOMIZATIONS
    • RELATED REPORTS
    • AUTHOR DETAILS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook